Category: Research news

Gene therapy for dogs could help RP patients

June 8, 2018

A US clinician has received a five-year, £6.1 million grant to investigate the potential of advancing a gene therapy currently used in dogs to help retinitis pigmentosa patients. Michigan State …

Researchers develop a new CRISPR technique to restore retinal function in mice with RP

May 29, 2018

Researchers from Columbia University have developed a new technique for the powerful gene editing tool CRISPR to restore retinal function in mice with retinitis pigmentosa. This is the first time …

Researchers create a retina cell network on a chip modelled after a humans neural network

May 10, 2018

Scientists have developed a new lab-on-a-chip technology that could quickly screen potential drugs to repair damaged neurons and retinal connections. Such damage is seen in people with RP, macular degeneration …

Increasing Eye Cells’ Ability to Process Misfolded Proteins May Prevent Retinal Degeneration

May 2, 2018

Researchers at Duke University believe they have developed an approach to treat retinal conditions (including retinitis pigmentosa), all of which create misfolded proteins that cells in the eye cannot process. …

First Patient Dosed in XLRP Treatment Trial

April 26, 2018

Applied Genetic Technologies Corporation has announced that the first patient was dosed in its Phase 1/2 clinical trial evaluating the safety and efficacy of AGTC-501 for the treatment of X-linked …

ReNeuron wins grant to advance development of stem cell therapy

April 24, 2018

UK-based developer of cell-based therapeutics, ReNeuron Group, has won a grant to advance the development of its hRPC stem cell therapy candidate for blindness-causing degenerative diseases of the retina. The …

ProQR Usher clinical development programme

April 18, 2018

ProQR is a young biotech firm based in the Netherlands that is in the early stages of planning a number of clinical trials targeting vision loss in Usher 2A patients …

Gene Therapy Trials for Best Disease could start in two years

March 27, 2018

Scientists in the U.S. say human trials of gene therapy for the inherited form of blindness known as vitelliform macular degeneration, or Best disease, could be less than two years …

Immune cells in the retina can spontaneously regenerate

March 26, 2018

Immune cells called microglia can completely repopulate themselves in the retina after being nearly eliminated, according to a new study in mice from scientists at the National Eye Institute (NEI). …

Nightstar Therapeutics announces initiation of STAR Phase III Registrational Trial for NSR-REP1 in Choroideremia

March 6, 2018

Nightstar Therapeutics PLC, a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, has announced the initiation of the company’s STAR Phase III registrational trial to study the …

MeiraGTx Receives EMA PRIME Designation for Achromatopsia Gene Therapy Candidate

March 5, 2018

MeiraGTx, a London and New York based gene therapy company, has announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to its gene therapy product candidate A002 …

Precision CRISPR repairs blindness in mice

February 14, 2018

In genome-editing, the challenge for CRISPR-wielding scientists is to edit only one of the two copies, or alleles, of every gene that people have, repairing the ever-so-slightly broken one and …